Asen combines his academic training in Pharmacology with industry experience in drug discovery to help advance the next generation of antibody therapies. With over two years at the Cambridge site of FairJourney Biologics, he has developed strong expertise in antibody discovery and engineering, spanning the full breadth of the drug development process—from initial target validation and antibody design to discovery and screening.

At RQ Biotechnology, Asen applies his research and wet-lab expertise to support the characterization of promising new therapeutics against infectious diseases, with the goal of safeguarding vulnerable populations.